Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1102 of 6351
-
Bladder cancer trial aims to save organs without sacrificing survival
Disease control CompletedThe aim of this study is to evaluate a risk-adapted approach to the treatment of muscle invasive bladder cancer. Each baseline transuretheral resection of bladder tumor (TURBT) sample will be sequenced while proceeding with neoadjuvant accelerated methotrexate, vinblastine, doxor…
Phase 2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
A 250,000-Person study aims to sharpen heart risk prediction with CT scans
Knowledge-focused Recruiting nowORFAN is a prospective, multi-centre, multi-ethnic cohort observational study collecting CT scans, biological material and outcomes data, to develop and validate novel biomarkers of cardiometabolic and other disease risk.
Sponsor: University of Oxford • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Promising combo tackles tough breast cancer
Disease control OngoingThe goal of this study is to establish the safety and tolerability of pembrolizumab when administered in combination with either of two chemotherapy regimens (weekly paclitaxel or capecitabine) in unresectable/metastatic triple negative breast cancer (MTNBC) patients.
Phase 1/2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Gene therapy injection shows promise for rare eye disease
Disease control CompletedThe goal of this clinical trial is to assess the effectiveness of GS010, a gene therapy, in improving the visual outcome in participants with Leber Hereditary Optic Neuropathy (LHON) due to the G11778A ND4 mitochondrial mutation when vision loss is present for six months or less.
Phase 3 • Sponsor: GenSight Biologics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug combo aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in…
Phase 1/2 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise in controlling Early-Stage leukemia
Disease control OngoingThis phase II trial studies how well dasatinib and venetoclax work in treating patients with Philadelphia chromosome positive or BCR-ABL1 positive early chronic phase chronic myelogenous leukemia. Dasatinib and venetoclax may stop the growth of tumor cells by blocking some of the…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for HER2 cancers: targeted drug shows promise in Mid-Stage trial
Disease control CompletedThe purpose of this study is to find out what effects, a drug called ado-trastuzumab emtansine has on the patient and their cancer which is thought to be controlled by the abnormal HER2 gene.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 09, 2026 16:00 UTC
-
New stem cell combo aims to beat childhood cancers
Disease control Recruiting nowThis phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patien…
Phase 1 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Immunotherapy drug shows promise for tough bladder cancer cases
Disease control Stopped earlyIn this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or have refused to undergo radical cystectomy, will receive pembrolizumab therapy or pembrolizumab in…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Stem cell injection aims to repair hearts after major attack
Disease control CompletedA multicentric controlled phase I / IIb study evaluating the safety and the efficacy of in vitro expanded peripheral blood CD34+ stem cells output by the StemXpand® Automated Process, and injected in patients with an acute myocardial infarction and a LVEF remaining below 50% vers…
Phase 2 • Sponsor: CellProthera • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Iron-Busting drug tested as Parkinson's slower
Disease control CompletedThis study evaluates the effect of iron chelation as a therapeutic strategy to slow the progression of Parkinson's disease. Half of participants will receive the deferiprone to 15 mg / kg twice daily morning and evening (30mg / kg per day), while the other half will receive a pla…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Can a pill mop up hidden leukemia cells after chemo?
Disease control CompletedThis phase II trial studies the side effects and how well ibrutinib works in treating patients with chronic lymphocytic leukemia who responded to initial treatment used to reduce a cancer (front-line therapy) but have residual disease. Ibrutinib may stop the growth of cancer cell…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug combo shows promise in shrinking aggressive breast tumors before surgery
Disease control CompletedThis phase II trial studies how well nab-paclitaxel and atezolizumab before surgery work in treating patients with triple negative breast cancer (breast cancer cells that do not have estrogen receptors, progesterone receptors, or large amounts of human epidermal growth factor rec…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
AI could read pain on the faces of silent ICU patients
Knowledge-focused OngoingThe objective of this project is to create deep learning and machine learning models capable of recognizing patient visual cues, including facial expressions such as pain and functional activity. Many important details related to the visual assessment of patients, such as facial …
Sponsor: University of Florida • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Which knee implant lasts longer? a Head-to-Head test
Disease control OngoingType \& Design: Post-market, international, multicentre Prospective, parallel groups, open-label, baseline controlled Objectives: 1. Assessment of clinical, radiographic and patient-reported outcomes of Physica CR and PS designs 2. Incidence of adverse events and identificatio…
Sponsor: Limacorporate S.p.a • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a pill combo replace chemo for some breast cancers?
Disease control OngoingThe purpose of this study is to determine if ribociclib in combination with letrozole for 24 weeks as neoadjuvant endocrine therapy increases the proportion of women with Pre-operative Endocrine Prognostic Index (PEPI) score of 0 at surgery compared to patients treated with letro…
Phase 2 • Sponsor: Qamar Khan • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Lung bath chemo during surgery aims to wipe out hidden sarcoma cells
Disease control Recruiting nowSarcoma which has spread to the lungs is most often treated with surgery. Even with surgery, most patients will not be cured and will die from their disease, probably because of small cancer cells that are present in the lungs at the time of surgery, but cannot be seen or detecte…
Phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Liver transplant breakthrough: new Clot-Busting technique saves grafts
Disease control CompletedBackground: To evaluate the safety and efficacy of intraoperative endovascular treatment (EVT) using the donor ligamentum teres hepatis (LTH) approach for Yerdel grade III/IV portal vein thrombosis (PVT) during liver transplantation (LT), a condition that poses a major challenge …
Sponsor: Chiyi Chen • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
A simple choice of IV fluid during surgery could change outcomes — which is safer?
Disease control CompletedThe primary purpose of the study is to evaluate whether the type of fluid (0.9% saline or 6% Hydroxyethyl starch 130/0.4) in the context of an individualized goal-directed fluid therapy is associated with a difference in morbidity and mortality within the first 14 days in patient…
Phase 3 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Promising combo therapy for infant leukemia enters human trials
Disease control OngoingThe purpose of this study is to test the good and bad effects of the study drugs bortezomib and vorinostat when they are given in combination with chemotherapy commonly used to treat acute lymphoblastic leukemia (ALL) in infants. For example, adding these drugs could decrease the…
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC